Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00482274 · ClinicalTrials.gov registry record · Phase 2
Docetaxel in Treating Patients With Relapsed Prostate Cancer
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00482274 is a Phase 2 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 3 participants.
The verdict
NCT00482274, a Phase 2 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well docetaxel works in treating patients with relapsed prostate cancer.
Interventions
- DRUG docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00482274
The ClinicalTrials.gov registry entry for NCT00482274 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which docetaxel is the first listed.
NCT00482274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00482274 about?
NCT00482274 is a clinical study titled "Docetaxel in Treating Patients With Relapsed Prostate Cancer". RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well docetaxel works in treating patients with relapsed prostate cancer.
What is the current status of trial NCT00482274?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2007-05. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00482274?
The interventions under investigation include: docetaxel (DRUG).
Who is sponsoring clinical trial NCT00482274?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.